Baird Medical Investment Holdings Ltd (BDMD) is not a strong buy for a beginner, long-term investor at this time. While the company has promising advancements in its microwave ablation technology and a strong gross margin, its financial performance is weak with negative net income and EPS. Additionally, the stock shows signs of being overbought based on RSI, and there are no significant trading trends or proprietary trading signals to suggest a compelling entry point.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 86.694, signaling an overbought condition. The stock's price is near its resistance level (R1: 2.267), suggesting limited upside potential in the short term.

Positive Catalysts

The company is making advancements in its microwave ablation technology, achieving clinical progress, and participating in major conferences to drive adoption among U.S. clinicians.

Neutral/Negative Catalysts

and EPS (-0.43). There are no significant trading trends or insider/hedge fund activity to support a buy decision.

Financial Performance

In 2024/Q2, revenue, net income, and EPS showed no year-over-year growth. Net income remains negative at -858731, and EPS is -0.43. Gross margin is strong at 82.11%, but it has not translated into profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast BDMD stock price to rise

Buy

Hold

Sell

Current: 2.980

Low

Averages

High